Skip to main
NKTX
NKTX logo

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc's strategic decision to reincorporate standardized lymphodepletion with fludarabine has significantly enhanced patient enrollment, indicating a positive momentum for the company's clinical trials. The firm is well-positioned as a "ground-floor" investment opportunity within the emerging category of engineered cell-based therapies, particularly due to its proprietary technologies aimed at optimizing the natural killer (NK) cell response against cancer. Additionally, Nkarta's focus on harnessing the intrinsic cytotoxicity of NK cells presents a compelling advantage over existing therapies, addressing many limitations associated with traditional CAR-T treatments and supporting a favorable growth outlook.

Bears say

Nkarta Inc reported a notable reduction in both research and development (R&D) spending by 14% sequentially to $21 million, which raises concerns about the company's ability to innovate and advance its NK cell therapies. Additionally, selling, general, and administrative (SG&A) expenses decreased significantly by 48%, suggesting potential constraints in operational capacity that could impact future growth initiatives. Furthermore, the planned protocol amendment in May 2025, which includes the reincorporation of fludarabine, may limit the robustness of conclusions drawn from clinical disclosures, indicating potential challenges in the company's ongoing and future clinical trial efforts.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.